Armata Pharmaceuticals, Inc.
ARMP- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000921114
No open-market purchases or sales by Armata Pharmaceuticals, Inc. insiders were filed in the last 90 days; 53 institutions reported holding it in 13F filings for Q2 2026, worth $32.3M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Armata Pharmaceuticals, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- +1 vs. Q2 2022
- Shares held
- 1.36M
- +8.56K (+0.6%) vs. Q2 2022
- Total value
- $5.73M
- +$485.0K (+9.2%) vs. Q2 2022
- New holders
- 2
- 3 more added
- Sold out
- 1
- 6 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARMP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 53 | $32.3M |
| Q1 2026 | 45 | $40.2M |
| Q4 2025 | 36 | $7.85M |
| Q3 2025 | 28 | $2.27M |
| Q2 2025 | 29 | $1.40M |
| Q1 2025 | 26 | $1.08M |
| Q4 2024 | 24 | $2.57M |
| Q3 2024 | 24 | $3.28M |
| Q2 2024 | 23 | $3.86M |
| Q1 2024 | 24 | $5.93M |
| Q4 2023 | 25 | $4.17M |
| Q3 2023 | 23 | $3.85M |
| Q2 2023 | 22 | $1.35M |
| Q1 2023 | 23 | $2.06M |
| Q4 2022 | 26 | $1.61M |
| Q3 2022 | 20 | $5.73M |
| Q2 2022 | 19 | $5.25M |
| Q1 2022 | 20 | $6.61M |
| Q4 2021 | 17 | $7.25M |
| Q3 2021 | 20 | $4.32M |
| Q2 2021 | 21 | $4.59M |
| Q1 2021 | 23 | $5.62M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Armata Pharmaceuticals, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 633,944 | $2.67M | 0.00% | −586−0.1% | Reduced |
| Vanguard Group Inc | 287,350 | $1.21M | 0.00% | +14,200+5.2% | Added |
| Bridgeway Capital Management, LLC | 113,682 | $480.0K | 0.01% | 00.0% | Unchanged |
| Edgewood Management LLC | 100,000 | $422.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 69,796 | $295.0K | 0.00% | −10,200−12.8% | Reduced |
| Synovus Financial Corp | 47,903 | $202.0K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 24,008 | $101.0K | 0.00% | +2,370+11.0% | Added |
| Geode Capital Management, LLC | 22,528 | $95.0K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 19,380 | $82.0K | 0.00% | 00.0% | Unchanged |
| SeaCrest Wealth Management, LLC | 17,550 | $74.0K | 0.01% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 13,072 | $56.0K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 5,500 | $23.0K | 0.00% | +5,500 | New |
| UBS Group AG | 1,875 | $8.00K | 0.00% | −1,256−40.1% | Reduced |
| Tower Research Capital LLC (TRC) | 904 | $4.00K | 0.00% | −209−18.8% | Reduced |
| Northwestern Mutual Wealth Management Co | 571 | $2.00K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 134 | $1.00K | 0.00% | +91+211.6% | Added |
| Morgan Stanley | 1 | $0 | 0.00% | −1,070−99.9% | Reduced |
| Wells Fargo & Company | 73 | $0 | 0.00% | −8−9.9% | Reduced |
| Salem Investment Counselors Inc | 100 | $0 | 0.00% | 00.0% | Unchanged |
| Householder Group Estate & Retirement Specialist, LLC | 136 | $0 | 0.00% | +136 | New |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −408−100.0% | Sold out |